Biocept (NASDAQ:BIOC) issued its quarterly earnings data on Monday. The medical research company reported ($0.38) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.19), Morningstar.com reports. The company had revenue of $1.19 million for the quarter. Biocept had a negative return on equity of 338.61% and a negative net margin of 695.85%.
Shares of NASDAQ:BIOC opened at $1.04 on Wednesday. The stock has a market cap of $19.25 million, a P/E ratio of -0.12 and a beta of 1.93. The company has a quick ratio of 2.63, a current ratio of 2.72 and a debt-to-equity ratio of 0.10. Biocept has a twelve month low of $0.66 and a twelve month high of $4.02. The business’s 50 day moving average is $1.04.
Several analysts have recently weighed in on BIOC shares. Maxim Group restated a “buy” rating and set a $3.00 price objective on shares of Biocept in a research report on Thursday, May 9th. ValuEngine upgraded shares of Biocept from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.
Biocept Company Profile
Biocept, Inc, an early stage molecular oncology diagnostics company, develops and commercializes proprietary circulating tumor cell (CTC) and circulating tumor DNA assays utilizing a standard blood sample. The company's cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring in order to identify resistance mechanisms.
Featured Article: How to interpret Moving Average Convergence Divergence (MACD)
Receive News & Ratings for Biocept Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biocept and related companies with MarketBeat.com's FREE daily email newsletter.